Navigation Links
MedQuist Announces Declaration of $2.75 per share Dividend on Common Stock
Date:7/14/2008

MOUNT LAUREL, July 14 /PRNewswire-FirstCall/ -- MedQuist Inc. (Pink Sheets: MEDQ) today announced that its board of directors declared a dividend of $2.75 per share on MedQuist's common stock. The dividend will be paid on August 4, 2008 to shareholders of record as of the close of business on July 25, 2008.

Newcastle Partners, L.P., along with other holders of MedQuist's common stock, have filed a shareholder derivative lawsuit in the Superior Court of New Jersey, Chancery Division, seeking, among other things, to enjoin the payment of a substantial dividend. Though the court denied Newcastle's request for a temporary restraining order enjoining the declaration of the dividend, it has set July 31, 2008 as a date for a hearing regarding a preliminary injunction enjoining a substantial dividend. If the court issues the requested injunctive relief and the dividend declared by the board is enjoined, it will be paid on the first practicable business day following the lifting or expiration of the injunction.

About MedQuist:

MedQuist is the largest Medical Transcription Service Organization (MTSO) in the world, and a leader in technology-enabled clinical documentation workflow. MedQuist's enterprise solutions -- including mobile voice capture devices, speech recognition, Web-based workflow platforms, and global network of medical editors -- help healthcare facilities improve patient care, increase physician satisfaction, and lower operational costs. For more information, please visit http://www.medquist.com.

Disclosure Regarding Forward-Looking Statements:

Some of the statements in this press release constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are not historical facts but rather are based on the company's current expectations, estimates and projections regarding the company's business, operations and other factors relating thereto. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expects," "intends," "plans," "projects," "believes," "estimates" and similar expressions are used to identify these forward-looking statements. The forward-looking statements contained in this press release include, without limitation, statements about the timing of the payment of the declared dividend and the hearing regarding a preliminary injunction enjoining a substantial dividend. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, including, without limitation, the risk that the settlement agreement is not consummated, the risk that the case is not dismissed with prejudice, and the risk of possible future claims against the company. For a discussion of these risks, uncertainties and assumptions, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of the company's Annual Report on Form 10-K for the year ended December 31, 2007, entitled "Risk Factors" and discussions of potential risks and uncertainties in the MedQuist's subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE MedQuist Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition
2. MedQuist Announces Dismissal of South Broward Litigation and Appointment of New Interim President & CEO
3. MedQuist to Get New Majority Stakeholder
4. MedQuist Technology Solutions to Power Documentation Workflow at New England Facility
5. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
6. Leading Arizona Radiological Group Selects MedQuist for Speech Recognition Solution
7. MedQuist Announces Appointment of Brian ODonoghue and Mark E. Schwarz to its Board of Directors
8. MedQuist Files Preliminary Proxy Statement and Applies for Listing on NASDAQ
9. MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders
10. MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions
11. MedQuist Updates Status of Outstanding SEC Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated ... Institute. For Betsy, the clinical trial has been life-saving as she has been ... , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Mary Magdalene: ... the mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace ... denizen, who spent her career as an educator interacting with countless women who had ...
(Date:1/20/2017)... ... , ... “I Forgive You”: a fine examination of how God handles sin, including how ... published author, Stephen Miller, who, for over ten long years has been waiting to release ... Trinidad and Tobago, he has been serving the Lord for over twenty years, and he ...
(Date:1/20/2017)... ... ... to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. ... in Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes ... back of my mind for years, but actually doing it might have been a while ...
(Date:1/20/2017)... ... ... “God's Miracle Man: Against All Odds”: an inspiring affirmation of God’s ... C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native who lives ... , “While sitting up in bed, I felt a pounding headache. It was like ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, ... anti-obesity drugs market is expected to grow at a CAGR ... CAGR of 38.7% in the second half of the forecast period. ... from 2016 to 2027. The market is estimated at $1,058 million ... ...
(Date:1/19/2017)... , January 19, 2017 ... European Oncology & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement ... journal from touchONCOLOGY, an article by James ...
(Date:1/19/2017)...   Science Exchange , the leading marketplace ... the first five replication studies from the ... in eLife today. Despite intense scrutiny around reproducibility ... evaluation of reproducibility rates that may identify specific ... assessments of reproducibility, the results of this project ...
Breaking Medicine Technology: